Marshall L. Michener

Author

Also Known As

M L Michener, M. L. MICHENER, M. L. Michener, M.L. Michener, MARSHALL L. MICHENER, Marshall L. Michener, Marshall Michener

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)Monsanto (United States)University of Virginia Washington University in St. Louis

About

Marshall L. Michener is an author at Pfizer (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	266
2	Biochemistry	2	2	94
3	Natural Sciences	1	1	35
4	Social Sciences	1	1	10
5	Cell Biology	1	1	76

Marshall L. Michener

Publications

471

Citations

H-Index

Page 1

	Year	Citations
Macrophage-colony stimulating factor and interleukin-34 induce chemokines in human whole blood Hiroyuki Eda, Jian Zhang, Robert H. Keith, Cytokine InflammationCytokineChemokine BiologyHuman Whole BloodInterleukin-34 Induce Chemokines	2010	76
Proteolytic processing of atriopeptin prohormone. Marshall L. Michener, James K. Gierse, Ramnath Seetharam, Molecular Pharmacology	1986	68
Measurement of Specific Protease Activity Utilizing Fluorescence Polarization Leanna Levine, Marshall L. Michener, Mihaly V. Toth, Analytical Biochemistry Proteomic TechnologyBioanalysisBiochemistry	1997	59
Phosphorylation of a chromaffin granule-binding protein in stimulated chromaffin cells. Marshall L. Michener, W B Dawson, Carl E. Creutz Journal of Biological Chemistry	1986	54
Is atriopeptin a physiological or pathophysiological substance? Studies in the autoimmune rat. James E. Greenwald, Moriyuki Sakata, Marshall L. Michener, Journal of Clinical Investigation HypertensionPrior ImmunizationPathophysiological SubstanceOxidative StressRenal Function	1988	52
Autoradiographic localization of atriopeptin III receptors in rat kidney Kenneth M. Murphy, Laura L. McLaughlin, Marshall L. Michener, European Journal of Pharmacology MedicinePhysiologyReceptor (Biochemistry)Autoradiographic LocalizationVascular Biology	1985	48
Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode Marvin J. Meyers, Matthew J. Pelc, Satwik Kamtekar, Bioorganic & Medicinal Chemistry Letters Drug TargetSignal TransductionMedicineReceptor Tyrosine KinasePharmacology	2010	35
Kelatorphan and related analogs: potent and selective inhibitors of leukotriene A4 hydrolase Thomas D. Penning, Leslie J. Askonas, Stevan W. Djurić, Bioorganic & Medicinal Chemistry Letters OxysterolAldehyde DehydrogenaseLeukotriene A4 HydrolaseBiochemistryMedicine	1995	35
A peptide isolated by phage display binds to ICAM-1 and inhibits binding to LFA-1 Joseph K. Welply, Christina N. Steininger, Maire H. Caparon, Proteins Structure Function and Bioinformatics	1996	24
Angiotensin III-induced modulation of neurogenic responses in the rabbit vas deferens and portal vein George J. Trachte, Edmund J. Sybertz, Marshall L. Michener, Naunyn-Schmiedeberg s Archives of Pharmacology NeurophysiologyMedicineRabbit Vas DeferensPhysiologyPortal Vein	1984	10

Page 1